Background: Persistent erythema and severe rosacea flushing can cause significant physical discomfort and emotional stress to patients. Currently, no satisfactory treatments are available. Methods: We report two cases of refractory flushing and erythema of rosacea that were successfully treated with intradermal botulinum toxin injections. Results: Good cosmetic results were achieved for both patients. The side effects during and after treatment were mild pain and localized bruising; these symptoms resolved within several days without further treatment. Conclusion: Intradermal botulinum toxin injection may be an effective treatment for refractory erythema and rosacea flushing that deserves further study in a larger patient population.

Journal Section:
Editor's choice
Keywords:
Botulinum toxin, Erythema, Flushing, Rosacea, Refractory
1.
Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F: Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46:584-587.
[PubMed]
https://doi.org/10.1067/mjd.2002.120625
2.
Hsu CC, Lee JY: Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker. J Am Acad Dermatol 2012;67:491-493.
[PubMed]
https://doi.org/10.1016/j.jaad.2012.04.017
3.
Wilkin JK: Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983;119:211-214.
[PubMed]
https://doi.org/10.1001/archderm.1983.01650270029012
4.
Bernstein JE, Soltani K: Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol 1982;107:59-61.
[PubMed]
https://doi.org/10.1111/j.1365-2133.1982.tb00290.x
5.
Wollina U: The response of erythematous rosacea to ondansetron. Br J Dermatol 1999;140:561-562.
[PubMed]
https://doi.org/10.1046/j.1365-2133.1999.02744.x
6.
Schram AM, James WD: Neurogenic rosacea treated with endoscopic thoracic sympathectomy. Arch Dermatol 2012;148:270-271.
[PubMed]
https://doi.org/10.1001/archdermatol.2011.2615
7.
Chen S: Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) 2012;4:913-939.
[PubMed]
https://doi.org/10.3390/toxins4100913
8.
Dayan SH, Pritzker RN, Arkins JP: A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol 2012;11:e76-e79.
[PubMed]
9.
Schantz EJ, Johnson EA: Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997;40:317-327.
[PubMed]
https://doi.org/10.1353/pbm.1997.0032
10.
Albanese A: Discussion of unique properties of botulinum toxins. Toxicon 2009;54:702-708.
[PubMed]
https://doi.org/10.1016/j.toxicon.2009.02.003
11.
Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C: Different types of botulinum toxin in humans. Mov Disord 2004;19(suppl 8):S53-S59.
[PubMed]
https://doi.org/10.1002/mds.20010
12.
Sampaio C, Costa J, Ferreira JJ: Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19(suppl 8): S129-S136.
[PubMed]
https://doi.org/10.1002/mds.20066
13.
Tugnoli V, Marchese Ragona R, Eleopra R, Quatrale R, Capone JG, Pastore A, Montecucco C, De Grandis D: The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. Clin Auton Res 2002;12:174-178.
[PubMed]
https://doi.org/10.1007/s10286-002-0026-x
14.
Wang X, Thirumala PD, Shah A, Gardner P, Habeych M, Crammond DJ, Balzer J, Horowitz M: Effect of previous botulinum neurotoxin treatment on microvascular decompression for hemifacial spasm. Neurosurg Focus 2013;34:E3.
[PubMed]
https://doi.org/10.3171/2012.11.FOCUS12373
15.
Khan TT, Herne K, Dayan SH, Woodward JA: Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg 2013;39:24-29.
[PubMed]
https://doi.org/10.1111/dsu.12057
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.